Abstracts tagged "signal transduction and therapeutic targeting"

Abstract Number: 844 • 2018 ACR/ARHP Annual Meeting
Differential Roles of Tnfα-TNFR1 and Tnfα-TNFR2 in the Differentiation and Function of Induced CD4+Foxp3+ Treg Cells in Autoimmune Diseases
SONGGUO ZHENG¹, Su-juan Yang², Julie Wang¹ and Rayford June¹, ¹Medicine, Milton S. Hershey Medical School at Penn State University, HERSHEY, PA, ²Medicine, The Third Affiliated Hospital at Sun Yat-sen University, Guangzhou, China
Background/Purpose: Tumor Necrosis Factor (TNF) α exerts it pro-inflammatory or anti-inflammatory function. This study hypothesizes that TNFα has multi-function through binding the different receptor 1…
Abstract Number: 2283 • 2016 ACR/ARHP Annual Meeting
Suppression of Monosodium Urate (MSU) Crystals-Induced Inflammatory Response By Inhibiting TGF-β Activated Kinase 1 (TAK1)
Anil Singh¹, Kayla O’Sullivan², Mukesh Chourasia³, Sadiq Umar⁴, Mahamudul Haque², Bhanupriya Madarampalli² and Salahuddin Ahmed², ¹Washington State University, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India, ⁴Department of Pharmaceutical Science, Washington State University, College of Pharmacy, Spokane, WA
Background/Purpose: Methods: Results: Conclusion:
Abstract Number: 2879 • 2014 ACR/ARHP Annual Meeting
Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh¹, Sharayah Riegsecker², Sadiq Umar¹ and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, ²Department of Pharmacology, University of Toledo, Toledo, OH
Background/Purpose: In rheumatoid arthritis (RA), the role of interleukin-1β (IL-1β) signaling proteins (IRAK-1/TAK-1/TRAF-6) proximal to IL-1 receptor in mediating proinflammatory response is not completely understood.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].